Heejae Kang, MD, PhD
- Resident, UPMC Medical Education, Pittsburgh, PA
Education & Training
- University of California, Berkeley, BA, 2010
- University of Pittsburgh, PhD, 2020
- University of Pittsburgh, MD, 2021
McAuley JR, Bailey KM, Ekambaram P, Kang H, Hu D, Freeman TJ, Klei LR, Concel VJ, Hubel NE, Sekar P, Bridwell RE, Covic L, Lucas PC#, and McAllister-Lucas LM# (2018) MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types. Oncogene, 38:7384-7398
Cheng J, Klei LR, Hubel NE, Zhang M, Schairer R, Maurer LM, Klei HB, Kang, H, Concel VJ, Delekta PC, Dang EV, Mintz MA, Baens M, Cyster JG, Parameswaran N, Thome M, Lucas PC#, and McAllister-Lucas LM# (2020) GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein. J. Clin. Invest., 130:1036-1051
Cheng J, Maurer LM, Kang H, Lucas PC, McAllister-Lucas LM. Critical protein-protein interactions within the CARMA1-BCL10-MALT1 complex: Take-home points for the cell biologist. Cell Immunol. 2020 Sep;355:104158. doi: 10.1016/j.cellimm.2020.104158. Epub 2020 Jul 7. PMID: 32721634.
Weick J, Kang H, Lee L, Kuether J, Liu X, Hansen E, Kandemir U, Rollins M, Mok J. Direct measurement of tissue oxygenation as a method of diagnosis of acute compartment syndrome. J Orthop Trauma. 2016 Nov;30(11):585-591.
Targeting protein-protein interactions in the CARMA-BCL10-MALT1 complex for the treatment of NF-kB-addicted lymphoid malignancies (Mentor: Dr. Peter Lucas)
Gwendolyn Sowa, MD, PhD
Peter Lucas, MD, PhD
Discovery of novel small molecule inhibitors of Bcl10-MALT1 interaction for the treatment of aggressive diffuse large B-cell lymphoma.
2013 - 2021